Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ingibjorg, Sigvaldadottir"'
Autor:
Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage, Per Johnsson
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy.
Externí odkaz:
https://doaj.org/article/f88ae22862f24b9684552bdca23e8edf
Autor:
Marianne Frostvik Stolt, Rainer Tuominen, Dan Grandér, Ishani Das, Per Johnsson, Aldwin Suryo Rahmanto, Johan Hansson, Håkan Olsson, Göran Jönsson, Sakari Kauppinen, Alireza Azimi, Christian Ingvar, Linda Vidarsdottir, Ingibjorg Sigvaldadottir, Andreas Petri, Olle Sangfelt, Katja Pokrovskaja Tamm, Suzanne Egyhazi Brage
Publikováno v:
Vidarsdottir, L, Azimi, A, Das, I, Sigvaldadottir, I, Suryo Rahmanto, A, Petri, A, Kauppinen, S, Ingvar, C, Jönsson, G, Olsson, H, Frostvik Stolt, M, Tuominen, R, Sangfelt, O, Pokrovskaja Tamm, K, Hansson, J, Grandér, D, Egyházi Brage, S & Johnsson, P 2021, ' PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma ', Scientific Reports, vol. 11, no. 1, 11023 . https://doi.org/10.1038/s41598-021-89389-9
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450435b6413ba470b4e369e6f91f03c9
https://vbn.aau.dk/da/publications/4126c388-b76b-418b-bab9-cd4b3824935b
https://vbn.aau.dk/da/publications/4126c388-b76b-418b-bab9-cd4b3824935b
Autor:
Linda, Vidarsdottir, Rita Valador, Fernandes, Vasilios, Zachariadis, Ishani, Das, Elin, Edsbäcker, Ingibjorg, Sigvaldadottir, Alireza, Azimi, Veronica, Höiom, Johan, Hansson, Dan, Grandér, Suzanne, Egyházi Brage, Katja, Pokrovskaja Tamm
Publikováno v:
Melanoma Research
Supplemental Digital Content is available in the text.
Introduction of targeted therapy in the treatment of metastatic cutaneous malignant melanoma (CMM) has improved clinical outcome during the last years. However, only in a subset of the CMM p
Introduction of targeted therapy in the treatment of metastatic cutaneous malignant melanoma (CMM) has improved clinical outcome during the last years. However, only in a subset of the CMM p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cc16ab5971f3b1441f0ba4bec3d99d64
https://pubmed.ncbi.nlm.nih.gov/32467529
https://pubmed.ncbi.nlm.nih.gov/32467529
Autor:
Göran Jönsson, Katja Pokrovskaja, Marianne Frostvik-Stolt, Andreas Petri, Dan Grandér, Håkan Olsson, Sakari Kauppinen, Rainer Tuominen, Linda Vidarsdottir, Alireza Azimi, Olle Sangfelt, Per Johnsson, Johan Hansson, suzanne Egyhazi-Brage, Aldwin Suryo Rahmanto, Christian Ingvar, Ingibjorg Sigvaldadottir
Approximately 50% of human cutaneous melanomas carry activating mutations in the serine/threonine protein kinase BRAF. BRAF inhibitors (BRAFi) selectively target the oncogenic BRAFV600E/K and are effective in approximately 80% of patients carrying th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97eb6995566fafd202c10d56ebbe344e